145 related articles for article (PubMed ID: 33417086)
1. Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy.
Soares ICS; Bello MA; Bergmann A; Thuler LCS
Breast Cancer Res Treat; 2021 Jun; 187(2):547-555. PubMed ID: 33417086
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Bergquist JR; Murphy BL; Storlie CB; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 Nov; 24(12):3510-3517. PubMed ID: 28828583
[TBL] [Abstract][Full Text] [Related]
3. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
Mittendorf EA; Vila J; Tucker SL; Chavez-MacGregor M; Smith BD; Symmans WF; Sahin AA; Hortobagyi GN; Hunt KK
JAMA Oncol; 2016 Jul; 2(7):929-36. PubMed ID: 26986538
[TBL] [Abstract][Full Text] [Related]
4. Validation of the CPS+EG and Neo-Bioscore staging systems after preoperative systemic therapy for breast cancer in a single center in China.
Xu L; Duan X; Zhou B; Liu Y; Ye J; Liu Z; Ma C; Zhang H; Zhang S; Zhang L; Zhao J; Cheng Y
Breast; 2018 Aug; 40():29-37. PubMed ID: 29677568
[TBL] [Abstract][Full Text] [Related]
5. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Resende U; Cabello C; Ramalho SOB; Zeferino LC
BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
[TBL] [Abstract][Full Text] [Related]
6. Validation of CPS+EG, Neo-Bioscore, and modified Neo-Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China.
Xu L; Zhang Z; Liu Q; Zhou B; Liu Y; Xiang Q; Zhu S; Duan X; Cui Y
Thorac Cancer; 2018 Nov; 9(11):1565-1572. PubMed ID: 30296013
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.
Kantor O; Laws A; Pastorello RG; King C; Wong S; Dey T; Schnitt S; King TA; Mittendorf EA
Ann Surg Oncol; 2021 Nov; 28(12):7347-7355. PubMed ID: 33956276
[TBL] [Abstract][Full Text] [Related]
8. Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.
Marmé F; Lederer B; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Jackisch C; Kümmel S; Loibl S; Paepke S; Untch M; von Minckwitz G; Schneeweiss A
Eur J Cancer; 2016 Jan; 53():65-74. PubMed ID: 26693900
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Steenbruggen TG; van Seijen M; Janssen LM; van Ramshorst MS; van Werkhoven E; Vrancken Peeters MTDF; Wesseling J; Lips EH; Sonke GS
Clin Cancer Res; 2019 Aug; 25(16):4985-4992. PubMed ID: 31076546
[TBL] [Abstract][Full Text] [Related]
10. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer.
Vila J; Teshome M; Tucker SL; Woodward WA; Chavez-MacGregor M; Hunt KK; Mittendorf EA
Ann Surg; 2017 Mar; 265(3):574-580. PubMed ID: 27735826
[TBL] [Abstract][Full Text] [Related]
11. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors.
Yi M; Lin H; Bedrosian I; Shen Y; Hunt KK; Chavez-MacGregor M; King TA; Mittendorf EA
Ann Surg Oncol; 2020 Feb; 27(2):359-366. PubMed ID: 31667721
[TBL] [Abstract][Full Text] [Related]
12. Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort Study.
Xu L; Liu Y; Fan Z; Jiang Z; Liu Y; Ling R; Zhang J; Yu Z; Jin F; Wang C; Cui S; Wang S; Mao D; Han B; Wang T; Zhang G; Wang T; Guo B; Yu L; Xu Y; Fu F; Liu Z; Wang S; Luo K; Xiang Q; Zhang Z; Liu Q; Zhou B; Liu Z; Ma C; Tong W; Mao J; Duan X; Cui Y
Front Oncol; 2021; 11():606477. PubMed ID: 33796452
[TBL] [Abstract][Full Text] [Related]
13. Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy.
Hasegawa Y; Matsubara N; Kogawa T; Naito Y; Harano K; Hosono A; Onishi T; Hojo T; Shimokawa M; Mukohara T
In Vivo; 2021; 35(2):1041-1049. PubMed ID: 33622900
[TBL] [Abstract][Full Text] [Related]
14. Validation of the CPS + EG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Abdelsattar JM; Al-Hilli Z; Hoskin TL; Heins CN; Boughey JC
Ann Surg Oncol; 2016 Oct; 23(10):3206-11. PubMed ID: 27328945
[TBL] [Abstract][Full Text] [Related]
15. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.
Mittendorf EA; Jeruss JS; Tucker SL; Kolli A; Newman LA; Gonzalez-Angulo AM; Buchholz TA; Sahin AA; Cormier JN; Buzdar AU; Hortobagyi GN; Hunt KK
J Clin Oncol; 2011 May; 29(15):1956-62. PubMed ID: 21482989
[TBL] [Abstract][Full Text] [Related]
16. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Roussot N; Constantin G; Desmoulins I; Bergeron A; Arnould L; Beltjens F; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Jacinto S; Michel E; Amet A; Coutant C; Costa B; Jouannaud C; Deblock M; Levy C; Ferrero JM; Kerbrat P; Brain E; Mouret-Reynier MA; Coudert B; Bertaut A; Ladoire S
Eur J Cancer; 2024 May; 202():114037. PubMed ID: 38554542
[TBL] [Abstract][Full Text] [Related]
17. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Marmé F; Solbach C; Michel L; Schneeweiss A; Blohmer JU; Huober J; Fasching PA; Jackisch C; Nekljudova V; Link T; Rhiem K; Rey J; Denkert C; Hanusch C; Tesch H; Lederer B; Loibl S; Untch M
Eur J Cancer; 2021 Aug; 153():203-212. PubMed ID: 34186505
[TBL] [Abstract][Full Text] [Related]
18. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
19. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]